Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00038636 · ClinicalTrials.gov registry record · Phase 3
A Study of Two Different Doses of ABT-378/Ritonavir in HIV-Infected Patients Who Have Taken Protease Inhibitors and Non-Nucleoside Reverse Transcriptase Inhibitors
A Phase 3 study, sponsored by Abbott.
- Completed
- Registry status
- Phase 3
- Development phase
- 36
- Enrollment target
NCT00038636 is a Phase 3 study that has completed, run by Abbott. The registered enrollment target is 36 participants.
The verdict
NCT00038636, a Phase 3 study, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 36 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and effectiveness of a high dose of ABT-378/ritonavir
Interventions
- DRUG Ritonavir
- DRUG Lopinavir/ritonavir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2000-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00038636
The ClinicalTrials.gov registry entry for NCT00038636 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott, which has 181 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ritonavir is the first listed.
NCT00038636 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00038636 about?
NCT00038636 is a clinical study titled "A Study of Two Different Doses of ABT-378/Ritonavir in HIV-Infected Patients Who Have Taken Protease Inhibitors and Non-Nucleoside Reverse Transcriptase Inhibitors". The purpose of this study is to determine the safety and effectiveness of a high dose of ABT-378/ritonavir
What is the current status of trial NCT00038636?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 36 participants. The study started on 2000-09.
What interventions are being tested in trial NCT00038636?
The interventions under investigation include: Ritonavir (DRUG), Lopinavir/ritonavir (DRUG).
Who is sponsoring clinical trial NCT00038636?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.